Logo image of VERU

VERU INC (VERU) Stock Fundamental Analysis

NASDAQ:VERU - Nasdaq - US92536C1036 - Common Stock - Currency: USD

0.653  -0.02 (-2.9%)

Premarket: 0.65 0 (-0.46%)

Fundamental Rating

3

Overall VERU gets a fundamental rating of 3 out of 10. We evaluated VERU against 195 industry peers in the Pharmaceuticals industry. While VERU seems to be doing ok healthwise, there are quite some concerns on its profitability. VERU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VERU has reported negative net income.
In the past year VERU has reported a negative cash flow from operations.
VERU had negative earnings in 4 of the past 5 years.
VERU had a negative operating cash flow in each of the past 5 years.
VERU Yearly Net Income VS EBIT VS OCF VS FCFVERU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

VERU has a Return On Assets of -96.59%. This is in the lower half of the industry: VERU underperforms 73.33% of its industry peers.
Looking at the Return On Equity, with a value of -144.48%, VERU is doing worse than 64.10% of the companies in the same industry.
Industry RankSector Rank
ROA -96.59%
ROE -144.48%
ROIC N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
VERU Yearly ROA, ROE, ROICVERU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

VERU has a Gross Margin of 39.70%. This is in the better half of the industry: VERU outperforms 60.51% of its industry peers.
In the last couple of years the Gross Margin of VERU has declined.
VERU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
VERU Yearly Profit, Operating, Gross MarginsVERU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

VERU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VERU has been increased compared to 1 year ago.
The number of shares outstanding for VERU has been increased compared to 5 years ago.
Compared to 1 year ago, VERU has an improved debt to assets ratio.
VERU Yearly Shares OutstandingVERU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
VERU Yearly Total Debt VS Total AssetsVERU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

VERU has an Altman-Z score of -8.62. This is a bad value and indicates that VERU is not financially healthy and even has some risk of bankruptcy.
VERU has a Altman-Z score of -8.62. This is in the lower half of the industry: VERU underperforms 69.23% of its industry peers.
VERU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.62
ROIC/WACCN/A
WACC10.06%
VERU Yearly LT Debt VS Equity VS FCFVERU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

VERU has a Current Ratio of 4.47. This indicates that VERU is financially healthy and has no problem in meeting its short term obligations.
VERU has a Current ratio of 4.47. This is in the better half of the industry: VERU outperforms 66.15% of its industry peers.
A Quick Ratio of 4.47 indicates that VERU has no problem at all paying its short term obligations.
The Quick ratio of VERU (4.47) is better than 67.18% of its industry peers.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47
VERU Yearly Current Assets VS Current LiabilitesVERU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

VERU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.00%, which is quite impressive.
The Revenue has been growing slightly by 3.62% in the past year.
Measured over the past years, VERU shows a very negative growth in Revenue. The Revenue has been decreasing by -11.89% on average per year.
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%

3.2 Future

VERU is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.30% yearly.
The Revenue is expected to grow by 60.53% on average over the next years. This is a very strong growth
EPS Next Y21.31%
EPS Next 2Y2.16%
EPS Next 3Y-6.33%
EPS Next 5Y1.3%
Revenue Next Year-78.96%
Revenue Next 2Y-41.42%
Revenue Next 3Y-42.17%
Revenue Next 5Y60.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VERU Yearly Revenue VS EstimatesVERU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
VERU Yearly EPS VS EstimatesVERU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VERU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERU Price Earnings VS Forward Price EarningsVERU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERU Per share dataVERU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

A cheap valuation may be justified as VERU's earnings are expected to decrease with -6.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.16%
EPS Next 3Y-6.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VERU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERU INC

NASDAQ:VERU (6/12/2025, 8:00:02 PM)

Premarket: 0.65 0 (-0.46%)

0.653

-0.02 (-2.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners35.42%
Inst Owner Change-17.05%
Ins Owners10.62%
Ins Owner Change1.53%
Market Cap95.72M
Analysts81.82
Price Target2.81 (330.32%)
Short Float %11.5%
Short Ratio6.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.55%
Min EPS beat(2)20.51%
Max EPS beat(2)22.6%
EPS beat(4)2
Avg EPS beat(4)-0.97%
Min EPS beat(4)-28.68%
Max EPS beat(4)22.6%
EPS beat(8)5
Avg EPS beat(8)8.3%
EPS beat(12)5
Avg EPS beat(12)-8.84%
EPS beat(16)8
Avg EPS beat(16)1.35%
Revenue beat(2)1
Avg Revenue beat(2)-8.34%
Min Revenue beat(2)-100%
Max Revenue beat(2)83.32%
Revenue beat(4)3
Avg Revenue beat(4)7.3%
Min Revenue beat(4)-100%
Max Revenue beat(4)83.32%
Revenue beat(8)4
Avg Revenue beat(8)-4.34%
Revenue beat(12)5
Avg Revenue beat(12)-17.01%
Revenue beat(16)7
Avg Revenue beat(16)-12.43%
PT rev (1m)0%
PT rev (3m)-14.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)4.42%
EPS NY rev (3m)4.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.49
P/FCF N/A
P/OCF N/A
P/B 3.59
P/tB 4.85
EV/EBITDA N/A
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0.1
BVpS0.18
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -96.59%
ROE -144.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.7%
FCFM N/A
ROA(3y)-103.45%
ROA(5y)-68.61%
ROE(3y)-231.35%
ROE(5y)-150.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.76%
GM growth 5Y-12.64%
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.05%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z -8.62
F-Score4
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)217.76%
Cap/Depr(5y)171.53%
Cap/Sales(3y)2.29%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y21.31%
EPS Next 2Y2.16%
EPS Next 3Y-6.33%
EPS Next 5Y1.3%
Revenue 1Y (TTM)3.62%
Revenue growth 3Y-34.92%
Revenue growth 5Y-11.89%
Sales Q2Q%-100%
Revenue Next Year-78.96%
Revenue Next 2Y-41.42%
Revenue Next 3Y-42.17%
Revenue Next 5Y60.53%
EBIT growth 1Y42.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y63.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.21%
OCF growth 3YN/A
OCF growth 5YN/A